MariTide: What the Once-Monthly Obesity Injection Data Shows

MariTide — generic name maridebart cafraglutide — is an investigational obesity drug from Amgen built on a structure no approved weight loss medication uses.

Most GLP-1 medications are peptides: short chains of amino acids that the body clears within days. MariTide is a peptide-antibody conjugate. Two GLP-1-like peptides are chemically attached to a monoclonal antibody. Antibodies circulate in the body far longer than peptides do, which is what allows monthly rather than weekly dosing.

The mechanism is the genuinely surprising part. MariTide activates the GLP-1 receptor — familiar territory, the same pathway as semaglutide. But it also blocks the GIP receptor.

That's worth pausing on, because tirzepatide (Mounjaro, Zepbound) does the opposite: it *activates* GIP alongside GLP-1, and that dual activation is credited with its superior results in head-to-head data. Two drugs doing opposite things to the same receptor while both producing substantial weight loss is one of the more interesting open puzzles in obesity pharmacology.

The leading explanation comes from human genetics. People carrying loss-of-function variants in the GIP receptor gene tend to have lower body weight. That observation is what motivated the antagonist approach. One hypothesis is that chronic GIP receptor stimulation eventually causes the receptor to desensitize — meaning sustained agonism might functionally resemble antagonism over time. Nobody has settled this.

For context on how the approved medications work, see [how GLP-1 medications work](/blog/how-glp1-medications-work-mechanism-explained).

A substantial amount — and notably, the curve had not flattened when the trial ended.

The phase 2 results were presented at the American Diabetes Association's 85th Scientific Sessions and published simultaneously in the *New England Journal of Medicine* in 2025. Key findings at 52 weeks:

In people with obesity without type 2 diabetes: up to approximately 20% average weight loss, compared with 2.6% in the placebo group.

In people with obesity and type 2 diabetes: up to approximately 17% average weight loss, compared with 1.4% on placebo. Weight loss is consistently smaller in people with diabetes across every obesity drug studied, so this pattern was expected.

Blood sugar: HbA1c fell by up to 2.2 percentage points in the diabetes group — a large effect by any standard.

Cardiometabolic markers: improvements were seen across waist circumference, blood pressure, high-sensitivity C-reactive protein (an inflammation marker), and several lipid measures.

The detail that drew the most attention: weight loss had not plateaued at 52 weeks. In most obesity trials the curve flattens somewhere between month nine and month twelve. MariTide's was still descending, which suggests longer treatment could produce more — though that has to be demonstrated, not assumed.

For comparison, tirzepatide produced 20.9% at 72 weeks in SURMOUNT-1 and semaglutide 14.9% at 68 weeks in STEP 1. MariTide's numbers are in that range at a shorter timepoint, but cross-trial comparisons are unreliable — different populations, different protocols, different endpoints. The only trustworthy comparison is head-to-head, which is why [SURMOUNT-5](/blog/tirzepatide-vs-semaglutide-surmount-5-head-to-head) mattered so much.

Gastrointestinal, as with every drug in this class — but the pattern differed in an important way, and it shaped how phase 3 was designed.

The most common adverse events were nausea, vomiting, and constipation. What stood out was the timing: nausea and vomiting were described as predominantly mild, transient, and primarily associated with the first dose.

That's the flip side of monthly dosing. With a weekly medication, drug levels rise gradually over months of careful titration. With a single monthly injection, more drug enters at once, and the first exposure hits harder. Some phase 2 arms started at relatively high doses without gradual escalation, and discontinuation rates in those arms were high enough to concern analysts when the data was presented.

Amgen's response was to redesign the phase 3 dosing schedule with more gradual escalation — starting lower and stepping up over a longer period before reaching target dose. This is a familiar arc: semaglutide and tirzepatide both settled into their current four-week titration schedules for the same reason.

There's also a genuinely open question about flexibility. If a weekly medication causes intolerable nausea, you can hold or step down and feel better within a couple of weeks. With a monthly injection, once it's administered you're committed for the month. Whether that becomes a practical problem or a non-issue is something phase 3 will reveal.

The class-wide cautions apply here too — pancreatitis, gallbladder events, and the thyroid C-cell tumor warning carried by all GLP-1 receptor agonists. Those are covered in [gallbladder risk on GLP-1s](/blog/glp1-gallbladder-gallstones-risk-symptoms-what-to-know) and [thyroid safety](/blog/glp1-thyroid-safety-what-you-need-to-know).

Not soon. As of 2026 it remains an investigational drug with no FDA approval for any indication.

The phase 3 MARITIME program launched across 2024 and 2025 and is enrolling adults with obesity, obesity with type 2 diabetes, and obesity with cardiometabolic conditions. Amgen reported continued phase 3 enrollment in its 2026 financial updates.

The program is broader than weight alone. Amgen has described additional phase 3 work across cardiovascular disease, heart failure, kidney disease, and obstructive sleep apnea — including two dedicated trials, MARITIME-OSA-1 and MARITIME-OSA-2, in adults with moderate-to-severe obstructive sleep apnea who are overweight or obese, with and without PAP therapy.

That breadth follows the strategic lesson of the last few years: the SELECT trial's cardiovascular results transformed how semaglutide was covered by insurers, and FLOW did something similar for kidney outcomes. Obesity drugs are increasingly evaluated on organ outcomes rather than weight alone. See [what the SELECT trial found](/blog/glp1-heart-health-what-the-select-trial-found) and [the FLOW kidney data](/blog/glp1-kidney-health-flow-trial-what-it-means).

Realistic timeline: large phase 3 obesity programs typically run two to three years before submission, followed by roughly a year of regulatory review. Barring surprises, approval is unlikely before the late 2020s.

MariTide is also not alone. The next-generation pipeline includes [retatrutide](/blog/retatrutide-triple-agonist-what-the-triumph-trials-show), the triple agonist; [orforglipron](/blog/orforglipron-foundayo-oral-glp1-pill-attain-results), the oral small molecule; [CagriSema](/blog/cagrisema-redefine-1-trial-results-explained); and [survodutide](/blog/survodutide-glucagon-glp1-dual-agonist-what-trials-show). The broader landscape is mapped in [the next-generation GLP-1 pipeline](/blog/next-gen-glp-1-pipeline-retatrutide-orforglipron-amycretin-2026).

For some people, clearly. For others, possibly worse. It depends on what your obstacle is.

The case for monthly. Twelve injections a year instead of fifty-two is a meaningful reduction in burden. Adherence to weekly injectables in real-world settings is considerably lower than in clinical trials, and forgotten doses are a recurring problem — the practical fallout of which is covered in [what to do when you miss a dose](/blog/missed-glp1-dose-what-to-do-timing-guide). Monthly dosing also simplifies travel enormously: no weekly cold-chain planning, no explaining a pen at airport security every trip. And for people with genuine needle aversion, twelve is a different proposition from fifty-two.

The case against. Flexibility disappears. If a dose causes significant nausea, you cannot step down mid-month — you wait it out. If you develop a reason to stop quickly, the drug is already circulating. Weekly dosing allows fine adjustment in a way monthly dosing structurally cannot.

There's also a psychological dimension that's easy to underrate. A weekly injection is a weekly touchpoint with your treatment — a recurring prompt to notice how things are going. A monthly injection removes eleven of those prompts a year. For some people that's welcome relief; for others, the routine is part of what keeps the rest of the plan on track.

And none of it changes the fundamentals. Protein intake, resistance training, and muscle preservation matter identically regardless of dosing frequency. The medication changes appetite; it does not change what your body needs while losing weight rapidly.

The honest summary: MariTide's phase 2 data is genuinely promising and the mechanism is scientifically interesting. It is also years away, and phase 2 results have failed to replicate in phase 3 many times before. Worth watching, not worth waiting for if you have a treatment option available now.